All lobbying filings

S-3 GROUP

Lobbying for VIATRIS (MYLAN, INC) · Generics and specialty pharmaceutical company

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 18, 2025

Income

$60,000.00

What the client paid this registrant for the period.

Client based in

Pennsylvania

Official filing document

Lobbyists on this filing 5

ASHLEY DAVIS

Previously held: Special Assistant to the Homeland Security Director, Executive Office of the President; Deputy Director of Management and Administration, Executive Office of the President
MALLOY MCDANIEL

Previously held: Policy Advisor, Senate Minority Leader Mitch McConnell; Whip Liaison, Senate Majority Whip Mitch McConnell; Floor Assistant, Senate Majority Leader Trent Lott; Cloakroom Assistant, Office of the Republican Secretary
KRISTI REMINGTON

Previously held: Deputy Assistant Attorney General, US Department of Justice; Senior Counsel, House Government Reform Committee
SHIMON STEIN

Previously held: Senior Policy Advisory, House Majority Leader Eric Cantor, Program Manager, US Department of Justice, Legislative Correspondent, Senator John Ashcroft; Paid Intern, Representative Robert Aderholt
CHRISTOPHER BUKI

Previously held: Staff Assistant/Legislative Correspondent, Representative John Culberson; Legislative Assistant/Senior Legislative Assistant, Representative Bill Shuster; Legislative Director/Deputy Chief of Staff, Representative David McKinley

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 5

S 1302
Increasing Transparency in Generic Drug Applications Act
HR 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
S 527
Prescription Pricing for the People Act of 2025
S 1096
Preserve Access to Affordable Generics and Biosimilars Act
S 1041
Affordable Prescriptions for Patients Act

Lobbying activity 2

Health Issues

Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing

Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.